The Social Security Fund's annual report on Hold Positions has been revealed! A total of 52 new stocks entered the top ten circulating Shareholders list, with China Resources Double-Crane Pharmaceutical receiving the most Shareholding increases.

① With the continuous disclosure of the 2024 annual reports of listed companies, the Social Security Fund has newly entered the top ten circulating shareholders list of 52 individual stocks; ② Among them, China Resources Double-Crane Pharmaceutical has the highest number of new holdings by the Social Security Fund, reaching 3; ③ Attached is the list of A-shares where the number of newly added Institutions held by the Social Security Fund in the fourth quarter of 2024 ranks highest (attached table).

cls.cnMar 29 04:55 ET

The founder sold the controlling stake at a 30% premium. Will Shaanxi Kanghui Pharmaceutical still sell medications in the future? | Quick read of the announcement

① Kanghui Holdings transferred 22% of its shares in Shaanxi Kanghui Pharmaceutical at 24.70 yuan/share, reflecting a premium of 31.24% compared to the price before the suspension. ② The business scope of the transferee, Yuehe Zhichuang, does not include any mention related to pharmaceuticals.

cls.cnMar 20 11:04 ET

After two trading limit increases, Shaanxi Kanghui Pharmaceutical officially announced plans for a change in control, refuting rumors of a shell acquisition by Hengchang Pharmaceutical | Quick announcement summary.

① Due to the controlling shareholder planning a share transfer, Shaanxi Kanghui Pharmaceutical Stocks have been suspended from trading since the 19th. ② Shaanxi Kanghui Pharmaceutical stated that, aside from a small collaboration with Hengchang Pharmaceutical on a Business level, there is no related cooperation in terms of backdoor listing.

cls.cnMar 18 11:53 ET

Shanghai Xuerong Bio-Technology changes ownership, new actual controller sets a "hundred billion Market Cap" flag | Quick read announcement.

① The control of Shanghai Xuerong Bio-Technology has changed, with chairman Yang Yongping relinquishing the position of the company's controlling Shareholder and actual controller. ② Jiang Zhi, an entrepreneur from the Online Games industry, will become the new actual controller. He stated that he hopes to build Shanghai Xuerong Bio-Technology into a publicly traded company with a revenue of 10 billion and a Market Cap of 100 billion in the next 3 to 5 years.

cls.cnMar 12 21:49 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 5 19:05 ET